US firm ArriVent’s plunge shows risks facing China’s biotech expansion into global markets
US firm ArriVent BioPharma’s shares plummeted after a late-stage trial failure involving a cancer drug licensed from China, a setback that analysts said highlighted the challenges facing Chinese biotech companies expanding overseas.
New York-listed ArriVent closed down nearly 47 per cent on Tuesday after reporting that its cancer treatment firmonertinib failed to meet its main goal in a phase 3 trial.
Firmonertinib was originally developed by Shanghai Allist Pharmaceuticals to treat non-small...
此摘要由5News从媒体的公开信息源汇聚而成。 包含完整背景的全文在www.scmp.com — 内容归South China Morning Post - Business所有。
